<p>Biocon Biologics has inked an out-licensing pact with Japanese pharma major Yoshindo to sell two of its pipeline biosimilars in Japan.</p>.<p>The deal gives Yoshindo exclusive rights to sell Ustekinumab and Denosumab – developed and made by the Biocon Ltd arm – in Japan for an addressable market opportunity of about $700 million. Biocon Biologics will get an upfront license fee and additional payments on the achievement of certain milestones over the next few years.</p>.<p>They did not disclose the deal’s financial terms.</p>.<p>Biosimilars are copycat versions of biotech drugs. Ustekinumab is a biosimilar referencing Stelara that is used in treating several autoimmune conditions such as psoriasis, Crohn’s disease and ulcerative colitis.</p>.<p>Denosumab, a biosimilar referencing Prolia, is used to treat osteoporosis, which causes bones to become weak and brittle.</p>.<p>“Once approved, these products will expand our offering of affordable, high-quality biosimilars in the Japanese market and help address unmet patient needs in bone health and immunology therapy areas,” said Shreehas Tambe, the deputy chief executive officer of Biocon Biologics.</p>.<p>Yoshindo's understanding of biosimilars and experience in the Japanese market were key<br />factors in scoring a deal with Biocon, explained Tambe.</p>.<p>The two products are currently undergoing clinical development and it will take a couple of years before the launch, according to Biocon’s communications head Seema Ahuja.</p>.<p>Biocon Biologics is in the process of developing a total of 20 biosimilar assets, either independently or through strategic partnerships, to be sold globally.</p>
<p>Biocon Biologics has inked an out-licensing pact with Japanese pharma major Yoshindo to sell two of its pipeline biosimilars in Japan.</p>.<p>The deal gives Yoshindo exclusive rights to sell Ustekinumab and Denosumab – developed and made by the Biocon Ltd arm – in Japan for an addressable market opportunity of about $700 million. Biocon Biologics will get an upfront license fee and additional payments on the achievement of certain milestones over the next few years.</p>.<p>They did not disclose the deal’s financial terms.</p>.<p>Biosimilars are copycat versions of biotech drugs. Ustekinumab is a biosimilar referencing Stelara that is used in treating several autoimmune conditions such as psoriasis, Crohn’s disease and ulcerative colitis.</p>.<p>Denosumab, a biosimilar referencing Prolia, is used to treat osteoporosis, which causes bones to become weak and brittle.</p>.<p>“Once approved, these products will expand our offering of affordable, high-quality biosimilars in the Japanese market and help address unmet patient needs in bone health and immunology therapy areas,” said Shreehas Tambe, the deputy chief executive officer of Biocon Biologics.</p>.<p>Yoshindo's understanding of biosimilars and experience in the Japanese market were key<br />factors in scoring a deal with Biocon, explained Tambe.</p>.<p>The two products are currently undergoing clinical development and it will take a couple of years before the launch, according to Biocon’s communications head Seema Ahuja.</p>.<p>Biocon Biologics is in the process of developing a total of 20 biosimilar assets, either independently or through strategic partnerships, to be sold globally.</p>
